starting an AP or patients newly switching to CLZ. Groups A and B will be assessed at a single time point (week 0) whereas Group C will be assessed prospectively at weeks 0, 3, and 12 with the same measures collected. The following clinical measures and metabolic indices are collected at baseline, and if applicable, at follow up visits: the Questionnaire of Eating and Weight Patterns (QEWP), the Dutch Eating Behavior Questionnaire (DEBQ), the Power of Food Scale (POFS), the Positive and Negative Syndrome Scale (PANSS), the Gastrointestinal Symptom Rating Scale (GSRS), Exercise/Physical Activity Evaluation, body mass index, oral glucose tolerance test, lipid profile, and serum clozapine levels. We also collect fecal samples for DNA extraction and microbiome sequencing. We are currently performing a baseline comparison across groups A, B, and C in order to evaluate intrinsic differences between schizophrenia and healthy controls, as well as, effects of new AP exposure versus chronic exposure. The difference between analytical groups (i.e. groups A, B, and C) at different time points (i.e. baseline, week 3 and 6) for variables such as BMI and metabolic parameters marker change are analyzed using two-way repeated measures ANCOVA, including significant covariates. The relationship between different measures, such as body weight and metabolic parameters, GMB composition (abundance of each species), and AIWG will be tested using Spearman's correlation. Analysis of the Operational Taxonomic Unit network generated using QIIME will be further analyzed using linear discriminant analysis (LDA) effect size (LEfSe) method. This method uses LDA scores to estimate the effect size of differentially abundant taxa (at phyla, class or other levels) and ranks the relative difference of microbial taxa that discriminate groups with biological consistency and statistical significance. The GMB composition of within group weight gainers versus non-weight gainer will also be assessed in a subgroup of subjects using LEfSe. Results: To date, 17 patients enrolled (13 patients in group A (9 men, mean±SD age: 31.6 ± 5.1 years; BMI, 31.4 ± 5.5), two control in group B (1 men, mean±SD age: 29.0 ± 1.4 years; BMI, 30.3 ± 0.8), two in group C (1 men, mean±SD age: 30.0 ± 9.9 years; BMI, 25.8 ± 5.6)). Further analyses including GMB composition in each group are now being conducted. We are currently analyzing these individuals for their GMB composition and results will be presented at the SIRS meeting. Discussion: To our knowledge, this is the first study to assess GMB sample in SCZ and investigate the association the GMB and AP-induced metabolic side effects. Our study has the potential to help to unravel the role of GMB in SCZ and AP response. 
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T193. CHRONIC HALOPERIDOL TREATMENT

Research Center for Molecular Medicine of the Austrian Academy of Sciences
Background: Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) is the most widely used technique to assess putative neuroimmune abnormalities in vivo. However, the results of TSPO PET in schizophrenia patients are ambiguous. In particular, the influence of antipsychotic medication exposure has not been definitively tested. We have previously established that chronic exposure to two different antipsychotics resulted in increased density and amoeboid morphology of brain microglia, particularly in the cortex (ACC) and corpus striatum (STR) (Cotel et al., 2015) . Here we explore the consequences of such treatment on TSPO, in relation to changes in microglia. We hypothesize that chronic haloperidol treatment would increase the expression of TSPO in microglia and correlate with increased levels of circulating proinflammatory cytokines. Methods: Adult male Sprague-Dawley rats (12 week-old) were implanted with subcutaneous osmotic mini-pumps (ALZET® 2ML4) delivering a continuous dose of either common vehicle (20% β-cyclodextrin + 5% ascorbic acid) or haloperidol (2mg/kg/d) for 28 days (Kapur et al., 2003) . Plasma was collected before perfusing the animals with 4% buffered PFA. Brains were carefully removed and processed for immunostaining against Iba1 and TSPO. Levels of plasma cytokines were measured using the pro-inflammatory 9-plex panel from Meso Scale Discovery (MSD®). TSPO expression was measured by its area fraction using FIJI software (10 snaps per animal per brain region, 20x magnification) in the ACC, STR, hippocampus (HPC), secondary somatosensory cortex (S2), primary motor cortex (M1). Numbers of resting and amoeboid microglia were determined by unbiased stereology (Gundersen, 1987) in the ACC, STR, and HPC. The Cavalieri estimator (StereoInvestigator 12.0,MBF Bioscience) was used to determine the volume of these regions. Data were analyzed by t-tests corrected for multiple comparisons, using GraphPad Prism 6.0. Results: Only 5 cytokines from the panel were above the limit of detection. Of these, IL-6 is significantly increased in haloperidol-treated animals (+186%, p<.01). IL-10, IL-4, KC/GRO, and TNFα plasma levels were not significantly affected. In parallel, TSPO expression was significantly increased in the ACC (+56%, p<.01), the STR (+77%, p<.01) and the S2 (+158%, p<.001). In the STR, the density of both resting and amoeboid microglia were significantly elevated in the treatment group (+22%, p<.05 and +45%, p<.001, respectively). A 2-way ANOVA revealed a significant interaction between treatment and brain region for amoeboid but not resting microglia. Peripheral IL-6 levels correlated negatively with TSPO levels in the STR in saline and haloperidol-treated groups (r=-0.82 and r=-0.62, respectively, p<.05). In addition, KC/GRO, although not different between groups, correlated positively with TSPO levels in STR in controls (r=0.77, p<.05), but negatively in HPC, M1, and S2 after haloperidol treatment (r=-0.66, r=-0.62, r=-0.6, respectively, p<.05). Discussion: As hypothesized, TSPO expression is significantly affected by chronic haloperidol, with augmented levels in the ACC, STR and S2. These data are in line with an increased TSPO PET signal in medicated schizophrenia patients as compared to matched antipsychotic-naïve patients (Holmes et al., 2016) . Furthermore, these data confirm and extend our prior findings demonstrating that microglial activation is present already after 28 days of exposure to haloperidol and this effect is most prominent in the STR. Further investigations are needed to determine which cell types drive changes in TSPO (glia, endothelium, astrocytes) and how this relates to their functions at a molecular level. Background: Prenatal exposure to the viral mimic poly-I:C via the pregnant dam has been shown to lead to a broad spectrum of neuro-psychopathological features phenotypic of schizophrenia, recapitulating the well established link between maternal infection in pregnancy and increased schizophrenia risk in the offspring. We previously showed using longitudinal imaging that prenatal poly-I:C leads postnatally to volumetric brain abnormalities that precede the emergence of behavioral abnormalities (selective attention deficits and excessive response to amphetamine) in adulthood, and that an ultra-low dose of risperidone (RIS) given prior to "symptom" emergence, prevents the emergence of behavioral as well as structural brain deficits. Here we aimed at showing that the efficacy of RIS (assessed at adulthood) is a function of time of administration, with earlier but not later being effective. Methods: On gestation day 15, pregnant Wistar rats were injected IV with polyI:C (4 mg/kg/ml) or saline. Offspring received daily injections of RIS (0.045 mg/kg) at 4 different time windows (TW): PNDs 34-47 (TW1), PNDs 48-61 (TW2), PNDs 62-75 (TW3) or PNDs 106-120 (TW4), and underwent structural imaging (scanned on a 7.0 T/30 cm; Bruker, Rheinstetten, Germany) and behavioral assessment of amphetamine-induced activity (AIA) and latent inhibition (LI). Excessive AIA is considered to mimic the exacerbation of psychotic symptoms in response to amphetamine in schizophrenia patients. LI reflects the normal attentional capacity to ignore stimuli that were experienced as irrelevant in the past; disrupted LI is considered to reflect a failure to ignore irrelevant stimuli and is seen in amphetamine-treated rodents and humans, in schizotypal persons, and in acutely psychotic schizophrenia patients. Testing was conducted on PNDs >90 (for TWs 1-3) and PNDs 106 and 150 (for TW4).
T194. BRAIN STRUCTURAL AND BEHAVIORAL
Results: Poly-I:C offspring had larger lateral ventricles (LV) and smaller prefrontal cortex (PFC), striatal (STR) and hippocampal (HIP) volumes, as well as disrupted LI and enhanced AIA compared to their controls. The effects of RIS on these abnormalities was a function of the administration window. RIS was fully effective when given in TW1 (significant prenatal treatment x drug treatment interaction for each of the brain regions as well as for both behavioral indices, and significant differences between poly-ICvehicle but not between poly-I:C-RIS and the control groups). In TW2, RIS prevented all abnormalities with the exception of HIP volume reduction (statistics as above except for HIP region). In contrast, in both TW 3 and 4, RIS failed to prevent both structural and behavioral abnormalities (only main effect of prenatal treatment for volumetric and AIA measures and only prenatal treatment x preexposure interaction for LI). Discussion: These results provide the first demonstration that intervention must indeed be provided early in order to be effective, with efficacy declining as the animal matures. Furthermore, they provide strong support for structure-function relationship because there is no prevention of behavioral abnormalities without prevention of structural abnormalities. Finally, since at the 0.045mg/kg dose RIS is a selective 5HT2A/2C antagonist, our results suggest that such antagonism is a promising route for prevention in high risk individuals. 
Stanford University
Background: Schizophrenia is characterised by marked cognitive deficits that are central to the disability caused by the disorder. These deficits are present prior to the onset of schizophrenia, are severe by the time of first presentation and persist. They are thought to arise from a core problem in neural connectivity. Cortical connectivity can be measured using changes in the synchronous activity of the brain in the gamma band (30-100Hz) of the electroencephalogram. This study characterizes the profile of gamma synchrony and behavioural performance during higher-order cognitive processing in schizophrenia. Methods: Gamma synchrony was acquired during a Continuous Performance Test (CPT) in 59 young people with First Onset Schizophrenia (FOS) and 59 matched controls We quantitated synchrony for regions associated with the fronto-parietal attention and visual networks. Groups were compared on gamma synchrony for intrinsic (pre-stimulus), task-evoked change (relative to baseline) and absolute (not relative to baseline) measures. The relationship between gamma synchrony, CPT accuracy, psychopathology and functioning was also explored.
Results: FOS showed a reduced ability to modulate task-evoked changes in gamma synchrony, in the context of generally higher intrinsic and absolute synchrony, particularly in frontal regions. These gamma synchrony abnormalities in FOS were associated with performance on the CPT, but not with symptoms or functioning. Discussion: This study is the first to demonstrate that gamma synchrony abnormalities are not limited to perceptual or lower-order cognitive processing. Task-relevant changes in synchrony were constrained by an overall excess of intrinsic background synchrony that was unrelated or not amenable to modulation by specific task demands. This excess in regional synchrony disturbed functional connectivity in central executive circuits and affected cognitive performance but not symptomatically. The results are consistent with gamma synchrony being a measure of dysconnectivity, a core abnormality in schizophrenia. 
The excitatory/inhibitory imbalance theory is widely accepted in the pathology of autism spectrum disorder. Recent results suggest its relevance in the aetiology of schizophrenia as well (Jardri 2016 , Yang 2017 , Gao and Penzes 2015 . In order to discover the possibly altered neuronal composition in schizophrenia numerous studies have been focussing mainly on different cortical regions such as the ventromedial prefrontal cortex and dorsolateral prefrontal cortex. In particular, various interneuronal populations have been found altered. 2 However, relatively little is known about the neuroanatomical changes of subcortical structures, such as the caudate nucleus, in the pathology of schizophrenia. Methods: Therefore, we examined the immunohistochemical distribution of calretinin (CR) and NPY-immunopositive neurons in the caudate nucleus and the dorsolateral prefrontal cortex. The state of microglial activation was controlled by the detection of Iba1 and TMEM119. In order to corroborate our results obtained by immunohistochemistry (IHC) qPCR analyses were also conducted. Results: The present study provides evidence for the altered interneuronal composition of caudate nucleus in schizophrenia without signs of microglial activation. There were small, medium and large CR-immunopositive (CRip) interneurons detected in the caudate nucleus. There was a 32% decrease in the density of all CR-ip interneurons (p=0.020, statistical power=0.747) that was driven by the loss of the small CR-ip interneurons (p=0.017, statistical power=0.777) while the densities of the medium and large CR-ip and NPY-ip interneurons were not significantly altered (p=0.078, p=0.436, p=0.125, respectively). Our experiments were also extended to the dorsolateral prefrontal cortex (medial frontal gyrus and superior frontal gyrus) where no significant changes were seen by IHC. However, qPCR analyses revealed a trend of decreased CR mRNA levels in schizophrenia (p=0.061, statistical power=0.485) while returned no significant changes regarding mRNA levels of NPY, Iba1 and TMEM119. No significant interactions between variables were seen controlling for PMI, age and gender by univariate, multifactorial ANOVA. Discussion: We have discovered one of the most striking examples of altered neuronal densities in the forebrain in schizophrenia; a highly significant decrease in CR-ip neuronal density in the caudate nucleus. Future studies are warranted to elucidate neuronal inputs to CR-ip neurons in the caudate nucleus and whether they innervate local interneurons or medium spiny neurons. If they primarily regulate local interneurons they may disinhibit medium spiny neurons. If they directly innervate medium spiny neurons they may inhibit the principal cells of the striatum. It will also
